Pacific Biosciences of California's GAAP loss for 3 months of 2022 was $81.499 million, down 6.8% from $87.435 million in the prior year. Revenue increased 14.4% to $33.173 million from $28.997 million a year earlier.

Pacific Biosciences of California's GAAP loss for 2021 was $181.223 million, compared to a profit of $29.403 million in the previous year. Revenue increased 65.4% to $130.513 million from $78.893 million a year earlier.

Pacific Biosciences of California reported a GAAP loss of $111.894 million for 9M 2021, up 2.5 times from $45.532 million in the previous year. Revenues increased 82.6% to $94.494 million from $51.757 million a year earlier.

Pacific Biosciences completed its $800 million acquisition of Omniome, which is developing a short-read sequencing platform capable of high accuracy. Pacific Biosciences paid $300 million and 9.4 million of its common stock, and will pay an additional $200 million if certain milestones are reached.